RxDoctor Payments Data

Brian Lindman, MD

Cardiovascular Disease · Nashville, TNNPI 1124146683

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $37,689 of the $56,353 with a category attached, or 66.9%. 5 manufacturers reported payments, led by Medtronic at 48.4% of the total. 2025 is the largest year on record at $21,363, more than ten times the $1,266 reported in 2019. Among cardiovascular disease clinicians in TN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$56,353in general payments, 2019–2025

Across 114 payments — averaging $494.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$27K
  • Edwards Lifesciences$22K
  • Astrazeneca UK Limited$5K
  • Boston Scientific$847
  • Abbott$553
$5,404,551in research payments, 2019–2025

Across 255 payments — averaging $21,194 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Edwards Lifesciences$5M
  • Boston Scientific$349K
  • Abbott$29K

What the payments were for

  • Consulting fees$37,68967%
  • Speaking & faculty fees$6,62512%
  • Travel & lodging$7,00712%
  • Food & beverage$5,0339%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Medtronic(2 entities)27$27,301
Edwards Lifesciences70$22,282
Astrazeneca UK Limited2$5,370
Boston Scientific9$847
Abbott6$553

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$56,353 in reported general payments places this provider in the 90th percentile of 429 cardiovascular disease providers in Tennessee.

See all cardiovascular disease providers in Tennessee

Medicare billing

Part B allowed, 2024
$12,707
Medicare patients
436
Services billed
498

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other cardiovascular disease in Nashville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →